Free Circulating Tumor DNA as a Diagnostic Marker for Breast Cancer
Background Cell‐free DNA (cfDNA) in the plasma of patients with both malignant and benign breast lesions was analyzed to determine whether the findings may have diagnostic and prognostic implications and to analyze the association between the levels of cfDNA and prognostic parameters. Methods Plasma...
Saved in:
| Published in | Journal of clinical laboratory analysis Vol. 26; no. 6; pp. 467 - 472 |
|---|---|
| Main Authors | , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Blackwell Publishing Ltd
01.11.2012
John Wiley & Sons, Inc John Wiley and Sons Inc |
| Subjects | |
| Online Access | Get full text |
| ISSN | 0887-8013 1098-2825 1098-2825 |
| DOI | 10.1002/jcla.21548 |
Cover
Loading…
| Abstract | Background
Cell‐free DNA (cfDNA) in the plasma of patients with both malignant and benign breast lesions was analyzed to determine whether the findings may have diagnostic and prognostic implications and to analyze the association between the levels of cfDNA and prognostic parameters.
Methods
Plasma samples were obtained from 99 subjects; 42 with breast cancer (BC), 30 with benign breast lesions, and 27 healthy women as normal controls. Circulatory cfDNA was extracted from the plasma samples and quantified using a real‐time quantitative PCR method. Immunohistochemistry was done on formalin‐fixed paraffin‐embedded sections to evaluate the status of hormonal receptors (estrogen receptor [ER] and progesterone receptor [PR]), and the protein expression of both Her2/neu and Topoisomerase IIα.
Results
The level of cfDNA in the BC group was significantly higher than in the benign lesions and control groups. cfDNA level was associated with malignant tumor size, lymph node involvement, stage, and grade as well as Her2/neu and Topoisomerase IIα expression, while it was not associated with ER or PR status.
Conclusions
The present study suggests that the level of cfDNA can be easily quantified using plasma samples. Thus, level of plasma cfDNA might constitute an important noninvasive diagnostic and prognostic valuable tool in cancer breast patients’ management. |
|---|---|
| AbstractList | Background Cell-free DNA (cf DNA ) in the plasma of patients with both malignant and benign breast lesions was analyzed to determine whether the findings may have diagnostic and prognostic implications and to analyze the association between the levels of cf DNA and prognostic parameters. Methods Plasma samples were obtained from 99 subjects; 42 with breast cancer (BC), 30 with benign breast lesions, and 27 healthy women as normal controls. Circulatory cf DNA was extracted from the plasma samples and quantified using a real-time quantitative PCR method. Immunohistochemistry was done on formalin-fixed paraffin-embedded sections to evaluate the status of hormonal receptors (estrogen receptor [ER] and progesterone receptor [PR]), and the protein expression of both Her2/neu and Topoisomerase II[alpha]. Results The level of cf DNA in the BC group was significantly higher than in the benign lesions and control groups. cf DNA level was associated with malignant tumor size, lymph node involvement, stage, and grade as well as Her2/neu and Topoisomerase II[alpha] expression, while it was not associated with ER or PR status. Conclusions The present study suggests that the level of cf DNA can be easily quantified using plasma samples. Thus, level of plasma cf DNA might constitute an important noninvasive diagnostic and prognostic valuable tool in cancer breast patients' management. Background Cell-free DNA (cfDNA) in the plasma of patients with both malignant and benign breast lesions was analyzed to determine whether the findings may have diagnostic and prognostic implications and to analyze the association between the levels of cfDNA and prognostic parameters. Methods Plasma samples were obtained from 99 subjects; 42 with breast cancer (BC), 30 with benign breast lesions, and 27 healthy women as normal controls. Circulatory cfDNA was extracted from the plasma samples and quantified using a real-time quantitative PCR method. Immunohistochemistry was done on formalin-fixed paraffin-embedded sections to evaluate the status of hormonal receptors (estrogen receptor [ER] and progesterone receptor [PR]), and the protein expression of both Her2/neu and Topoisomerase II[alpha]. Results The level of cfDNA in the BC group was significantly higher than in the benign lesions and control groups. cfDNA level was associated with malignant tumor size, lymph node involvement, stage, and grade as well as Her2/neu and Topoisomerase II[alpha] expression, while it was not associated with ER or PR status. Conclusions The present study suggests that the level of cfDNA can be easily quantified using plasma samples. Thus, level of plasma cfDNA might constitute an important noninvasive diagnostic and prognostic valuable tool in cancer breast patients' management. [PUBLICATION ABSTRACT] Background Cell‐free DNA (cfDNA) in the plasma of patients with both malignant and benign breast lesions was analyzed to determine whether the findings may have diagnostic and prognostic implications and to analyze the association between the levels of cfDNA and prognostic parameters. Methods Plasma samples were obtained from 99 subjects; 42 with breast cancer (BC), 30 with benign breast lesions, and 27 healthy women as normal controls. Circulatory cfDNA was extracted from the plasma samples and quantified using a real‐time quantitative PCR method. Immunohistochemistry was done on formalin‐fixed paraffin‐embedded sections to evaluate the status of hormonal receptors (estrogen receptor [ER] and progesterone receptor [PR]), and the protein expression of both Her2/neu and Topoisomerase IIα. Results The level of cfDNA in the BC group was significantly higher than in the benign lesions and control groups. cfDNA level was associated with malignant tumor size, lymph node involvement, stage, and grade as well as Her2/neu and Topoisomerase IIα expression, while it was not associated with ER or PR status. Conclusions The present study suggests that the level of cfDNA can be easily quantified using plasma samples. Thus, level of plasma cfDNA might constitute an important noninvasive diagnostic and prognostic valuable tool in cancer breast patients’ management. Cell-free DNA (cfDNA) in the plasma of patients with both malignant and benign breast lesions was analyzed to determine whether the findings may have diagnostic and prognostic implications and to analyze the association between the levels of cfDNA and prognostic parameters.BACKGROUNDCell-free DNA (cfDNA) in the plasma of patients with both malignant and benign breast lesions was analyzed to determine whether the findings may have diagnostic and prognostic implications and to analyze the association between the levels of cfDNA and prognostic parameters.Plasma samples were obtained from 99 subjects; 42 with breast cancer (BC), 30 with benign breast lesions, and 27 healthy women as normal controls. Circulatory cfDNA was extracted from the plasma samples and quantified using a real-time quantitative PCR method. Immunohistochemistry was done on formalin-fixed paraffin-embedded sections to evaluate the status of hormonal receptors (estrogen receptor [ER] and progesterone receptor [PR]), and the protein expression of both Her2/neu and Topoisomerase IIα.METHODSPlasma samples were obtained from 99 subjects; 42 with breast cancer (BC), 30 with benign breast lesions, and 27 healthy women as normal controls. Circulatory cfDNA was extracted from the plasma samples and quantified using a real-time quantitative PCR method. Immunohistochemistry was done on formalin-fixed paraffin-embedded sections to evaluate the status of hormonal receptors (estrogen receptor [ER] and progesterone receptor [PR]), and the protein expression of both Her2/neu and Topoisomerase IIα.The level of cfDNA in the BC group was significantly higher than in the benign lesions and control groups. cfDNA level was associated with malignant tumor size, lymph node involvement, stage, and grade as well as Her2/neu and Topoisomerase IIα expression, while it was not associated with ER or PR status.RESULTSThe level of cfDNA in the BC group was significantly higher than in the benign lesions and control groups. cfDNA level was associated with malignant tumor size, lymph node involvement, stage, and grade as well as Her2/neu and Topoisomerase IIα expression, while it was not associated with ER or PR status.The present study suggests that the level of cfDNA can be easily quantified using plasma samples. Thus, level of plasma cfDNA might constitute an important noninvasive diagnostic and prognostic valuable tool in cancer breast patients' management.CONCLUSIONSThe present study suggests that the level of cfDNA can be easily quantified using plasma samples. Thus, level of plasma cfDNA might constitute an important noninvasive diagnostic and prognostic valuable tool in cancer breast patients' management. Cell-free DNA (cfDNA) in the plasma of patients with both malignant and benign breast lesions was analyzed to determine whether the findings may have diagnostic and prognostic implications and to analyze the association between the levels of cfDNA and prognostic parameters. Plasma samples were obtained from 99 subjects; 42 with breast cancer (BC), 30 with benign breast lesions, and 27 healthy women as normal controls. Circulatory cfDNA was extracted from the plasma samples and quantified using a real-time quantitative PCR method. Immunohistochemistry was done on formalin-fixed paraffin-embedded sections to evaluate the status of hormonal receptors (estrogen receptor [ER] and progesterone receptor [PR]), and the protein expression of both Her2/neu and Topoisomerase IIα. The level of cfDNA in the BC group was significantly higher than in the benign lesions and control groups. cfDNA level was associated with malignant tumor size, lymph node involvement, stage, and grade as well as Her2/neu and Topoisomerase IIα expression, while it was not associated with ER or PR status. The present study suggests that the level of cfDNA can be easily quantified using plasma samples. Thus, level of plasma cfDNA might constitute an important noninvasive diagnostic and prognostic valuable tool in cancer breast patients' management. |
| Author | Sorour, A. Talaat, I. Ghazal, A. Hashad, D. |
| AuthorAffiliation | 3 Pathology Department Faculty of Medicine Alexandria University Alexandria Egypt 1 Clinical Pathology Department Faculty of Medicine Alexandria University Alexandria Egypt 2 General Surgery Department Faculty of Medicine Alexandria University Alexandria Egypt |
| AuthorAffiliation_xml | – name: 1 Clinical Pathology Department Faculty of Medicine Alexandria University Alexandria Egypt – name: 2 General Surgery Department Faculty of Medicine Alexandria University Alexandria Egypt – name: 3 Pathology Department Faculty of Medicine Alexandria University Alexandria Egypt |
| Author_xml | – sequence: 1 givenname: D. surname: Hashad fullname: Hashad, D. email: doaa_hashad2003@yahoo.com organization: Clinical Pathology Department, Faculty of Medicine, Alexandria University, Alexandria, Egypt – sequence: 2 givenname: A. surname: Sorour fullname: Sorour, A. organization: Clinical Pathology Department, Faculty of Medicine, Alexandria University, Alexandria, Egypt – sequence: 3 givenname: A. surname: Ghazal fullname: Ghazal, A. organization: General Surgery Department, Faculty of Medicine, Alexandria University, Alexandria, Egypt – sequence: 4 givenname: I. surname: Talaat fullname: Talaat, I. organization: Pathology Department, Faculty of Medicine, Alexandria University, Alexandria, Egypt |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/23143630$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkk9v1DAQxS1URLeFCx8AReKCkFI8_hN7L0hLym6BpXAogpvleCeLl2xc7ATotydhuxVUCHHyYX7v6XneHJGDNrRIyEOgJ0Ape7ZxjT1hIIW-QyZApzpnmskDMqFaq1xT4IfkKKUNpVRPobhHDhkHwQtOJ6ScR8Ss9NH1je18u84u-m2I2en5LLMps9mpt-s2pM677K2NXzBm9TB-EdGmLitt6zDeJ3dr2yR8cP0ekw_zlxflWb58t3hVzpa5k2IIxSWuFNXSTpmt6oopBFnVWtsK1FSxFbNAtVAapaxrEBWfOuTohERtXQUFPybPd76XfbXFlcO2i7Yxl9FvbbwywXrz56T1n806fDOFpkooOhg8uTaI4WuPqTNbnxw2jW0x9MmAEJqxYTP_gYIERYGJMdbjW-gm9LEdNmHGLTOhoBipR7-Hv0m9r2IA6A5wMaQUsTbOd0MlYfyLbwxQM7ZtxrbNr7YHydNbkr3rX2HYwd99g1f_IM3rcjnba_KdxqcOf9xohjswheJKmo_nC7N4Iz69n9Mzo_hPDtzHKA |
| CitedBy_id | crossref_primary_10_1007_s12609_016_0214_7 crossref_primary_10_1007_s13277_016_5001_6 crossref_primary_10_1586_14737159_2015_1110021 crossref_primary_10_1515_cclm_2021_0193 crossref_primary_10_1016_j_jmoldx_2017_06_004 crossref_primary_10_1038_bjc_2016_175 crossref_primary_10_3389_fonc_2019_00095 crossref_primary_10_1177_11769351221076062 crossref_primary_10_3390_cells8080862 crossref_primary_10_4174_astr_2014_86_3_136 crossref_primary_10_3109_07357907_2014_1001894 crossref_primary_10_3390_diagnostics13071241 crossref_primary_10_1016_j_bbcan_2016_03_006 crossref_primary_10_1016_j_cancergen_2018_02_002 crossref_primary_10_1016_j_ejca_2018_10_012 crossref_primary_10_1186_s13046_023_02743_9 crossref_primary_10_1016_j_mrrev_2019_05_002 crossref_primary_10_1038_s41598_021_87094_1 crossref_primary_10_3390_cancers13040728 crossref_primary_10_1186_s43046_024_00219_1 crossref_primary_10_1586_14737159_2013_845088 crossref_primary_10_18632_oncotarget_15120 crossref_primary_10_1177_0883073813503904 crossref_primary_10_3390_medsci9020037 crossref_primary_10_4155_cli_14_93 crossref_primary_10_1371_journal_pone_0077469 crossref_primary_10_1016_j_ejrad_2016_01_016 crossref_primary_10_3390_ijms140918925 crossref_primary_10_36384_01232576_6 crossref_primary_10_1016_j_oraloncology_2015_12_002 crossref_primary_10_2217_bmm_2020_0022 crossref_primary_10_3389_fmed_2018_00009 crossref_primary_10_3390_ijms241612690 crossref_primary_10_1089_gtmb_2018_0237 crossref_primary_10_3390_diseases8030034 crossref_primary_10_1016_j_bbacli_2017_03_006 crossref_primary_10_1515_cclm_2019_0436 crossref_primary_10_18632_oncotarget_21827 crossref_primary_10_1007_s12609_013_0125_9 crossref_primary_10_1371_journal_pone_0206601 crossref_primary_10_18632_oncotarget_8839 crossref_primary_10_3390_bios12080648 crossref_primary_10_1200_JCO_2012_45_2011 crossref_primary_10_1016_j_yexmp_2017_02_009 |
| Cites_doi | 10.1007/s00404-007-0345-1 10.1038/bjc.1996.286 10.1002/1097-0142(20000615)88:12 <3080::AID-CNCR27>3.0.CO;2-W 10.1038/sj.bjc.6603449 10.1089/dna.2008.0744 10.1007/s00268-009-0150-z 10.1200/JCO.2004.11.123 10.1186/1476-4598-8-105 10.1023/A:1014730829872 10.5858/2007-131-18-ASOCCO 10.1038/379225a0 10.1016/j.mrrev.2006.11.002 10.3121/cmr.2008.825 10.1016/j.ejca.2011.06.017 |
| ContentType | Journal Article |
| Copyright | 2012 Wiley Periodicals, Inc. |
| Copyright_xml | – notice: 2012 Wiley Periodicals, Inc. |
| DBID | BSCLL AAYXX CITATION CGR CUY CVF ECM EIF NPM 7QP 7T5 7U9 H94 K9. 7X8 7TM 5PM |
| DOI | 10.1002/jcla.21548 |
| DatabaseName | Istex CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Calcium & Calcified Tissue Abstracts Immunology Abstracts Virology and AIDS Abstracts AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic Nucleic Acids Abstracts PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Immunology Abstracts Virology and AIDS Abstracts Calcium & Calcified Tissue Abstracts MEDLINE - Academic Nucleic Acids Abstracts |
| DatabaseTitleList | Nucleic Acids Abstracts AIDS and Cancer Research Abstracts MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| DocumentTitleAlternate | Hashad et al |
| EISSN | 1098-2825 |
| EndPage | 472 |
| ExternalDocumentID | PMC6807470 3081502911 23143630 10_1002_jcla_21548 JCLA21548 ark_67375_WNG_GK4XPF0H_7 |
| Genre | article Journal Article |
| GroupedDBID | --- .3N .GA .GJ .Y3 05W 0R~ 10A 1L6 1OB 1OC 1ZS 24P 31~ 33P 3SF 3WU 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5RE 5VS 66C 6PF 702 7PT 7X7 8-0 8-1 8-3 8-4 8-5 8C1 8FI 8FJ 8UM 930 A01 A03 A8Z AAESR AAEVG AAHHS AAONW AAWTL AAZKR ABCQN ABEML ABIJN ABPVW ABUWG ACBWZ ACCFJ ACGFS ACMXC ACPRK ACSCC ACXQS ADBBV ADEOM ADIZJ ADKYN ADPDF ADZMN AEEZP AEIMD AENEX AEQDE AEUQT AFBPY AFKRA AFPWT AFZJQ AHMBA AIWBW AJBDE ALAGY ALIPV ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR ASPBG ATUGU AVUZU AVWKF AZBYB AZFZN AZVAB BAFTC BBNVY BCNDV BDRZF BENPR BFHJK BHBCM BHPHI BMXJE BROTX BRXPI BSCLL BY8 CCPQU CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DU5 DUUFO EBD EBS EJD EMOBN ESTFP F00 F01 F04 F1Z F5P FEDTE FUBAC FYUFA G-S G.N GNP GODZA GROUPED_DOAJ H.X HBH HCIFZ HF~ HHY HMCUK HVGLF HYE HZ~ IAO IHR ITC IX1 J0M JPC KQQ LAW LC2 LC3 LH4 LITHE LOXES LP6 LP7 LUTES LW6 M65 M7P MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM N04 N05 N9A NF~ NNB O66 O9- OIG OK1 OVD OVEED P2P P2W P2X P2Z P4B P4D PALCI PIMPY PQQKQ Q.N Q11 QB0 QRW R.K RGB RIWAO RJQFR ROL RPM RWI RX1 SAMSI SUPJJ SV3 TEORI TWZ UB1 UKHRP V2E W8V W99 WBKPD WHWMO WIB WIH WIJ WIK WIN WOHZO WQJ WRC WUP WVDHM WXI WXSBR XG1 XPP XV2 ~IA ~WT AANHP ACCMX ACRPL ACYXJ ADNMO AAYXX AGQPQ CITATION PHGZM PHGZT CGR CUY CVF ECM EIF NPM 7QP 7T5 7U9 AAMMB AEFGJ AGXDD AIDQK AIDYY H94 K9. 7X8 7TM 5PM |
| ID | FETCH-LOGICAL-c5498-35ed7085a92abfb27e15bf88ab17972d2a108478e55ff14b39ce3ec45e8acb163 |
| IEDL.DBID | DR2 |
| ISSN | 0887-8013 1098-2825 |
| IngestDate | Thu Aug 21 18:11:24 EDT 2025 Thu Jul 10 21:00:52 EDT 2025 Tue Aug 05 11:29:46 EDT 2025 Wed Aug 13 06:48:02 EDT 2025 Thu Apr 03 06:53:42 EDT 2025 Tue Jul 01 00:21:28 EDT 2025 Thu Apr 24 23:00:11 EDT 2025 Wed Jan 22 17:01:36 EST 2025 Wed Oct 30 09:52:31 EDT 2024 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 6 |
| Language | English |
| License | http://onlinelibrary.wiley.com/termsAndConditions#vor 2012 Wiley Periodicals, Inc. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c5498-35ed7085a92abfb27e15bf88ab17972d2a108478e55ff14b39ce3ec45e8acb163 |
| Notes | ArticleID:JCLA21548 istex:E9D339D10ACCD971511B1A96127AF0149442C5F7 ark:/67375/WNG-GK4XPF0H-7 ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 14 ObjectType-Article-1 ObjectType-Feature-2 content type line 23 |
| PMID | 23143630 |
| PQID | 1436247166 |
| PQPubID | 105667 |
| PageCount | 6 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_6807470 proquest_miscellaneous_1448224360 proquest_miscellaneous_1151701246 proquest_journals_1436247166 pubmed_primary_23143630 crossref_citationtrail_10_1002_jcla_21548 crossref_primary_10_1002_jcla_21548 wiley_primary_10_1002_jcla_21548_JCLA21548 istex_primary_ark_67375_WNG_GK4XPF0H_7 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | November 2012 |
| PublicationDateYYYYMMDD | 2012-11-01 |
| PublicationDate_xml | – month: 11 year: 2012 text: November 2012 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: New York – name: Hoboken |
| PublicationTitle | Journal of clinical laboratory analysis |
| PublicationTitleAlternate | J. Clin. Lab. Anal |
| PublicationYear | 2012 |
| Publisher | Blackwell Publishing Ltd John Wiley & Sons, Inc John Wiley and Sons Inc |
| Publisher_xml | – name: Blackwell Publishing Ltd – name: John Wiley & Sons, Inc – name: John Wiley and Sons Inc |
| References | Collins LC, Botero ML, Schnitt SJ. Bimodal frequency distribution of EstrogenReceptor immunohistochemical staining results in breast cancer. Am J ClinPathol 2005;123:16-20. Diel I, Solomayer E, Bastert G. Bisphosphonates and the prevention of metastasis: First evidences from preclinical and clinical studies. Cancer 2000;88:3080-3088. Gormally E, Caboux E, Vineis P, Hainaut P. Circulating free DNA in plasma or serum as biomarker of carcinogenesis: Practical aspects and biological significance. Mut Res 2007;635:105-117. Catarino R, Ferreira M, Rodrigues H, et al. Quantification of free circulating tumor DNA as a diagnostic marker for breast cancer. DNA Cell Biol 2008;27:415-420. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, editors. American Joint Committee on Cancer Staging Manual, seventh edition, New York: Springer; 2010. Catarino R, Ferreira M, Rodrigues H, et al. Quantification of free circulating tumor DNA as a diagnostic marker for breast cancer. DNA Cell Biol 2008;27:415-421. Kuzhan O, Ozet A, Ulutin C, et al. Impact of c-erb2 status on survival after high dose chemotherapy in high-risk breastcancer patients. Saudi Med J 2007;28:1374-1379. Sandri M, Hochhauser D, Ayton P, et al. Differential expression of the Topoisomerase II alpha and beta genes in human breast cancers. Br J Cancer 1996;73:1518-1524. Berger JM, Gamblin SJ, Harrison SC, et al. Structure and mechanism of DNA topoisomerase IIα. Nature 1996;379:225-232. Yasojima H, Shimmura A, Naoi Y, et al. Association between c-myc amplification and pathological complete response to neoadjuvant chemotherapy in breast cancer. Association between c-myc amplification and pathological complete response to neoadjuvant chemotherapy in breast cancer. Eur J Cancer 2011;47:1779-1788. Seedhom A, Kamal N. Factors affecting survival of women diagnosed with breast cancer in El-Minia governorate. Egypt Int J Prev Med 2011;2:131-138. Tavassoli F, Devilee P. World Health Organization Classification of Tumours: Tumors of the Breast and Female Genital Organs. Lyon: IARC Press, International Agency for Research on Cancer; 2003. p 18-19. Kohler C, Radpour R, Barekati Z, et al. Levels of plasma circulating cell free nuclear and mitochondrial DNA as potential biomarkers for breast tumors. Mol Cancer 2009;8:105-113. Agarwal G, Ramakant P, Forgach E, et al. Breast cancer care in developing countries. World J Surg 2009;33:2069-2076. Gautschi O, Bigosch C, Huegli B, et al. Circulating deoxyribonucleic acid as prognostic marker in non-small-cell lung cancer patients undergoing chemotherapy. J Clin Oncol 2004;22:4157-4164. Onitilo A, Engel J, Greenlee R, Mukesh B. Breast cancer subtypes based on ER/PR and Her2 expression: Comparison of clinicopathologic features and survival. Clin Med Res 2009;7:4-13. Jahr S, Hentze H, Englisch S, et al. DNA fragments in the blood plasma of cancer patients: Quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res 2001;61:1659-1665. Pantel K, Muller V, Auer M, et al. Detection and clinical implications of early systemic tumour cell dissemination in breast cancer. Clin Cancer Res 2003;9:6326-6334. Shao ZM, Wu J, Shen ZZ, Nguyen M. p53 mutationin plasma DNA and its prognostic value in breast cancer patients. Clin Cancer Res 2001;7: 2222-2227. Leon S, Shapiro B, Sklaroff D, et al. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res 1977;37:646-650. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology; College of American Pathologists. American Society of Clinical Oncology/College of American Pathologists Guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Path Lab Med 2007;131:18-43. Eccles S. The role of c-erbB-2/HER2/NEU/neu in breast cancer progression and metastasis. J Mammary Gland Biol Neoplasia 2002;6:393-406. Hannemann J, Kristel P, van Tinteren H, et al. Molecular subtypes of breast cancer and amplification of Topoisomerase IIa: Predictive role in dose intensive adjuvant chemotherapy. Br J Cancer 2006;95:1334-1341. Zhong X, Ladewig A, Schmid S, et al. Elevated level of cell-free plasma DNA is associated with breast cancer. Arch Gynecol Obstet 2007;276:327-331. 2007; 28 2009; 33 2004; 22 2001; 61 2007; 635 2011; 2 2006; 95 1977; 37 2001; 7 2010 2005; 123 2000; 88 2007; 276 2002; 6 2008; 27 2003; 9 2007; 131 1996; 73 2009; 8 2009; 7 2003 2011; 47 1996; 379 Shao ZM (e_1_2_7_22_1) 2001; 7 e_1_2_7_5_1 Jahr S (e_1_2_7_10_1) 2001; 61 Wolff AC (e_1_2_7_17_1) 2007; 131 e_1_2_7_3_1 e_1_2_7_9_1 Kuzhan O (e_1_2_7_6_1) 2007; 28 e_1_2_7_7_1 e_1_2_7_19_1 Tavassoli F (e_1_2_7_13_1) 2003 e_1_2_7_18_1 Seedhom A (e_1_2_7_2_1) 2011; 2 Leon S (e_1_2_7_8_1) 1977; 37 e_1_2_7_14_1 e_1_2_7_25_1 e_1_2_7_24_1 e_1_2_7_23_1 e_1_2_7_11_1 e_1_2_7_21_1 e_1_2_7_20_1 Collins LC (e_1_2_7_16_1) 2005; 123 Pantel K (e_1_2_7_4_1) 2003; 9 Edge SB (e_1_2_7_12_1) 2010 Onitilo A (e_1_2_7_15_1) 2009; 7 |
| References_xml | – reference: Shao ZM, Wu J, Shen ZZ, Nguyen M. p53 mutationin plasma DNA and its prognostic value in breast cancer patients. Clin Cancer Res 2001;7: 2222-2227. – reference: Berger JM, Gamblin SJ, Harrison SC, et al. Structure and mechanism of DNA topoisomerase IIα. Nature 1996;379:225-232. – reference: Gormally E, Caboux E, Vineis P, Hainaut P. Circulating free DNA in plasma or serum as biomarker of carcinogenesis: Practical aspects and biological significance. Mut Res 2007;635:105-117. – reference: Jahr S, Hentze H, Englisch S, et al. DNA fragments in the blood plasma of cancer patients: Quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res 2001;61:1659-1665. – reference: Hannemann J, Kristel P, van Tinteren H, et al. Molecular subtypes of breast cancer and amplification of Topoisomerase IIa: Predictive role in dose intensive adjuvant chemotherapy. Br J Cancer 2006;95:1334-1341. – reference: Diel I, Solomayer E, Bastert G. Bisphosphonates and the prevention of metastasis: First evidences from preclinical and clinical studies. Cancer 2000;88:3080-3088. – reference: Catarino R, Ferreira M, Rodrigues H, et al. Quantification of free circulating tumor DNA as a diagnostic marker for breast cancer. DNA Cell Biol 2008;27:415-420. – reference: Zhong X, Ladewig A, Schmid S, et al. Elevated level of cell-free plasma DNA is associated with breast cancer. Arch Gynecol Obstet 2007;276:327-331. – reference: Seedhom A, Kamal N. Factors affecting survival of women diagnosed with breast cancer in El-Minia governorate. Egypt Int J Prev Med 2011;2:131-138. – reference: Collins LC, Botero ML, Schnitt SJ. Bimodal frequency distribution of EstrogenReceptor immunohistochemical staining results in breast cancer. Am J ClinPathol 2005;123:16-20. – reference: Yasojima H, Shimmura A, Naoi Y, et al. Association between c-myc amplification and pathological complete response to neoadjuvant chemotherapy in breast cancer. Association between c-myc amplification and pathological complete response to neoadjuvant chemotherapy in breast cancer. Eur J Cancer 2011;47:1779-1788. – reference: Pantel K, Muller V, Auer M, et al. Detection and clinical implications of early systemic tumour cell dissemination in breast cancer. Clin Cancer Res 2003;9:6326-6334. – reference: Kuzhan O, Ozet A, Ulutin C, et al. Impact of c-erb2 status on survival after high dose chemotherapy in high-risk breastcancer patients. Saudi Med J 2007;28:1374-1379. – reference: Leon S, Shapiro B, Sklaroff D, et al. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res 1977;37:646-650. – reference: Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology; College of American Pathologists. American Society of Clinical Oncology/College of American Pathologists Guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Path Lab Med 2007;131:18-43. – reference: Kohler C, Radpour R, Barekati Z, et al. Levels of plasma circulating cell free nuclear and mitochondrial DNA as potential biomarkers for breast tumors. Mol Cancer 2009;8:105-113. – reference: Catarino R, Ferreira M, Rodrigues H, et al. Quantification of free circulating tumor DNA as a diagnostic marker for breast cancer. DNA Cell Biol 2008;27:415-421. – reference: Onitilo A, Engel J, Greenlee R, Mukesh B. Breast cancer subtypes based on ER/PR and Her2 expression: Comparison of clinicopathologic features and survival. Clin Med Res 2009;7:4-13. – reference: Tavassoli F, Devilee P. World Health Organization Classification of Tumours: Tumors of the Breast and Female Genital Organs. Lyon: IARC Press, International Agency for Research on Cancer; 2003. p 18-19. – reference: Eccles S. The role of c-erbB-2/HER2/NEU/neu in breast cancer progression and metastasis. J Mammary Gland Biol Neoplasia 2002;6:393-406. – reference: Gautschi O, Bigosch C, Huegli B, et al. Circulating deoxyribonucleic acid as prognostic marker in non-small-cell lung cancer patients undergoing chemotherapy. J Clin Oncol 2004;22:4157-4164. – reference: Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, editors. American Joint Committee on Cancer Staging Manual, seventh edition, New York: Springer; 2010. – reference: Agarwal G, Ramakant P, Forgach E, et al. Breast cancer care in developing countries. World J Surg 2009;33:2069-2076. – reference: Sandri M, Hochhauser D, Ayton P, et al. Differential expression of the Topoisomerase II alpha and beta genes in human breast cancers. Br J Cancer 1996;73:1518-1524. – volume: 2 start-page: 131 year: 2011 end-page: 138 article-title: Factors affecting survival of women diagnosed with breast cancer in El‐Minia governorate publication-title: Egypt Int J Prev Med – volume: 37 start-page: 646 year: 1977 end-page: 650 article-title: Free in the serum of cancer patients and the effect of therapy publication-title: Cancer Res – start-page: 18 year: 2003 end-page: 19 – volume: 7 start-page: 2222 year: 2001 end-page: 2227 article-title: p53 mutationin plasma and its prognostic value in breast cancer patients publication-title: Clin Cancer Res – volume: 61 start-page: 1659 year: 2001 end-page: 1665 article-title: fragments in the blood plasma of cancer patients: Quantitations and evidence for their origin from apoptotic and necrotic cells publication-title: Cancer Res – volume: 73 start-page: 1518 year: 1996 end-page: 1524 article-title: Differential expression of the Topoisomerase alpha and beta genes in human breast cancers publication-title: Br J Cancer – volume: 27 start-page: 415 year: 2008 end-page: 421 article-title: Quantification of free circulating tumor DNA as a diagnostic marker for breast cancer publication-title: DNA Cell Biol – volume: 7 start-page: 4 year: 2009 end-page: 13 article-title: Breast cancer subtypes based on / and er2 expression: Comparison of clinicopathologic features and survival publication-title: Clin Med Res – volume: 33 start-page: 2069 year: 2009 end-page: 2076 article-title: Breast cancer care in developing countries publication-title: World J Surg – volume: 27 start-page: 415 year: 2008 end-page: 420 article-title: Quantification of free circulating tumor as a diagnostic marker for breast cancer publication-title: DNA Cell Biol – volume: 276 start-page: 327 year: 2007 end-page: 331 article-title: Elevated level of cell‐free plasma is associated with breast cancer publication-title: Arch Gynecol Obstet – volume: 6 start-page: 393 year: 2002 end-page: 406 article-title: The role of c‐erbB‐2/ 2/ /neu in breast cancer progression and metastasis publication-title: J Mammary Gland Biol Neoplasia – volume: 28 start-page: 1374 year: 2007 end-page: 1379 article-title: Impact of c‐erb2 status on survival after high dose chemotherapy in high‐risk breastcancer patients publication-title: Saudi Med J – volume: 95 start-page: 1334 year: 2006 end-page: 1341 article-title: Molecular subtypes of breast cancer and amplification of Topoisomerase IIa: Predictive role in dose intensive adjuvant chemotherapy publication-title: Br J Cancer – volume: 22 start-page: 4157 year: 2004 end-page: 4164 article-title: Circulating deoxyribonucleic acid as prognostic marker in non‐small‐cell lung cancer patients undergoing chemotherapy publication-title: J Clin Oncol – volume: 9 start-page: 6326 year: 2003 end-page: 6334 article-title: Detection and clinical implications of early systemic tumour cell dissemination in breast cancer publication-title: Clin Cancer Res – volume: 47 start-page: 1779 year: 2011 end-page: 1788 article-title: Association between c‐myc amplification and pathological complete response to neoadjuvant chemotherapy in breast cancer. Association between c‐myc amplification and pathological complete response to neoadjuvant chemotherapy in breast cancer publication-title: Eur J Cancer – volume: 635 start-page: 105 year: 2007 end-page: 117 article-title: Circulating free in plasma or serum as biomarker of carcinogenesis: Practical aspects and biological significance publication-title: Mut Res – volume: 379 start-page: 225 year: 1996 end-page: 232 article-title: Structure and mechanism of topoisomerase α publication-title: Nature – volume: 131 start-page: 18 year: 2007 end-page: 43 article-title: American Society of Clinical Oncology; College of American Pathologists. American Society of Clinical Oncology/College of American Pathologists Guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer publication-title: Arch Path Lab Med – volume: 123 start-page: 16 year: 2005 end-page: 20 article-title: Bimodal frequency distribution of EstrogenReceptor immunohistochemical staining results in breast cancer publication-title: Am J ClinPathol – year: 2010 – volume: 8 start-page: 105 year: 2009 end-page: 113 article-title: Levels of plasma circulating cell free nuclear and mitochondrial as potential biomarkers for breast tumors publication-title: Mol Cancer – volume: 88 start-page: 3080 year: 2000 end-page: 3088 article-title: Bisphosphonates and the prevention of metastasis: First evidences from preclinical and clinical studies publication-title: Cancer – volume: 7 start-page: 2222 year: 2001 ident: e_1_2_7_22_1 article-title: p53 mutationin plasma DNA and its prognostic value in breast cancer patients publication-title: Clin Cancer Res – ident: e_1_2_7_23_1 doi: 10.1007/s00404-007-0345-1 – ident: e_1_2_7_19_1 doi: 10.1038/bjc.1996.286 – ident: e_1_2_7_5_1 doi: 10.1002/1097-0142(20000615)88:12 <3080::AID-CNCR27>3.0.CO;2-W – ident: e_1_2_7_7_1 doi: 10.1038/sj.bjc.6603449 – volume: 123 start-page: 16 year: 2005 ident: e_1_2_7_16_1 article-title: Bimodal frequency distribution of EstrogenReceptor immunohistochemical staining results in breast cancer publication-title: Am J ClinPathol – ident: e_1_2_7_14_1 doi: 10.1089/dna.2008.0744 – volume: 37 start-page: 646 year: 1977 ident: e_1_2_7_8_1 article-title: Free DNA in the serum of cancer patients and the effect of therapy publication-title: Cancer Res – ident: e_1_2_7_3_1 doi: 10.1007/s00268-009-0150-z – start-page: 18 volume-title: World Health Organization Classification of Tumours: Tumors of the Breast and Female Genital Organs year: 2003 ident: e_1_2_7_13_1 – volume-title: American Joint Committee on Cancer Staging Manual, year: 2010 ident: e_1_2_7_12_1 – ident: e_1_2_7_9_1 doi: 10.1200/JCO.2004.11.123 – ident: e_1_2_7_20_1 doi: 10.1186/1476-4598-8-105 – ident: e_1_2_7_24_1 doi: 10.1023/A:1014730829872 – volume: 28 start-page: 1374 year: 2007 ident: e_1_2_7_6_1 article-title: Impact of c‐erb2 status on survival after high dose chemotherapy in high‐risk breastcancer patients publication-title: Saudi Med J – volume: 131 start-page: 18 year: 2007 ident: e_1_2_7_17_1 article-title: American Society of Clinical Oncology; College of American Pathologists. American Society of Clinical Oncology/College of American Pathologists Guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer publication-title: Arch Path Lab Med doi: 10.5858/2007-131-18-ASOCCO – ident: e_1_2_7_25_1 doi: 10.1038/379225a0 – volume: 61 start-page: 1659 year: 2001 ident: e_1_2_7_10_1 article-title: DNA fragments in the blood plasma of cancer patients: Quantitations and evidence for their origin from apoptotic and necrotic cells publication-title: Cancer Res – ident: e_1_2_7_21_1 doi: 10.1089/dna.2008.0744 – volume: 9 start-page: 6326 year: 2003 ident: e_1_2_7_4_1 article-title: Detection and clinical implications of early systemic tumour cell dissemination in breast cancer publication-title: Clin Cancer Res – ident: e_1_2_7_11_1 doi: 10.1016/j.mrrev.2006.11.002 – volume: 7 start-page: 4 year: 2009 ident: e_1_2_7_15_1 article-title: Breast cancer subtypes based on ER/PR and Her2 expression: Comparison of clinicopathologic features and survival publication-title: Clin Med Res doi: 10.3121/cmr.2008.825 – ident: e_1_2_7_18_1 doi: 10.1016/j.ejca.2011.06.017 – volume: 2 start-page: 131 year: 2011 ident: e_1_2_7_2_1 article-title: Factors affecting survival of women diagnosed with breast cancer in El‐Minia governorate publication-title: Egypt Int J Prev Med |
| SSID | ssj0008916 |
| Score | 2.1804025 |
| Snippet | Background
Cell‐free DNA (cfDNA) in the plasma of patients with both malignant and benign breast lesions was analyzed to determine whether the findings may... Cell-free DNA (cfDNA) in the plasma of patients with both malignant and benign breast lesions was analyzed to determine whether the findings may have... Background Cell-free DNA (cfDNA) in the plasma of patients with both malignant and benign breast lesions was analyzed to determine whether the findings may... Background Cell-free DNA (cf DNA ) in the plasma of patients with both malignant and benign breast lesions was analyzed to determine whether the findings may... |
| SourceID | pubmedcentral proquest pubmed crossref wiley istex |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 467 |
| SubjectTerms | Antigens, Neoplasm - biosynthesis Benign Biomarkers, Tumor - blood Breast cancer Breast Neoplasms - blood Breast Neoplasms - diagnosis Breast Neoplasms - pathology Case-Control Studies cell free plasma DNA Deoxyribonucleic acid Diagnostic tests DNA DNA Topoisomerases, Type II - biosynthesis DNA, Neoplasm - blood DNA-Binding Proteins - biosynthesis Female Humans Neoplasm Staging Plasma Real-Time Polymerase Chain Reaction real-time quantitative PCR Receptor, ErbB-2 - biosynthesis Receptors, Estrogen - biosynthesis Receptors, Progesterone - biosynthesis |
| Title | Free Circulating Tumor DNA as a Diagnostic Marker for Breast Cancer |
| URI | https://api.istex.fr/ark:/67375/WNG-GK4XPF0H-7/fulltext.pdf https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fjcla.21548 https://www.ncbi.nlm.nih.gov/pubmed/23143630 https://www.proquest.com/docview/1436247166 https://www.proquest.com/docview/1151701246 https://www.proquest.com/docview/1448224360 https://pubmed.ncbi.nlm.nih.gov/PMC6807470 |
| Volume | 26 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ti9QwEB6OOxC_-P5SPY-IIih0r02apgW_rD33ltNbRG51ESQk2VRPz650d0H89U7SbtfV40C_FWYCTTKTeZJMngF4XJokjVOOnma4u2bUUahsxMJU81ioXPHcH-Ycj9LhODma8MkWPF-9hWn4IboDN-cZfr12Dq70fH9NGvrFnKkedYgbF2CXrOUQ0ds1d1SW-7qn3otwGWYdNyndXzfdiEY7bmB_nAc1_86Y_B3J-lA0uAofV51oMlC-9pYL3TM__-B3_N9eXoMrLUYl_caorsOWrW7ApeP2Fv4mFIPaWlKc1sbX_qo-kZPlt1lNDkZ9ouZEkYMmfw-bE_cWyNYEoTF54fLfF6RwdlbfgvHg5UkxDNtiDKHBLWQWMm6nAvGZyqnSpabCxlyXWaY0urSgU6riCCNdZjkvyzjRLDeWWZNwmymjEfXdhu1qVtm7QNTUkbwLoRNlEzalecxKjTiDlol13DcBPF1NijQtU7krmHEmG45lKt2oSD8qATzqdL83_Bznaj3xc9upYN9dRpvg8v3oUB6-SiZvBtFQigB2V5MvW2ee4-4IozwG8TQN4GEnRjd0dyuqsrMl6iByEhjsk4t0cCuMiImlUQB3GnvqfghhNgoYSsSGpXUKjgZ8U1KdfvZ04KnjMxLY8pk3pAuGQR4Vr_v-696_KN-HywgTafMCcxe2F_XSPkAottB7sNN_N_4w3vOu9wvCWy5J |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3fb9MwELZglYAXNH6HbWAEQgIpLLHjOHksGV3Z2oqHFqq9WLbrwNBIp6yV-PO5c7KMimkSb5XuLKVnn-87-_wdIW9Km6RxKsDTrMBrRhOF2kU8TI2Ipc61yP1hzniSDmfJ0VzM29ocfAvT8EN0B27oGX6_RgfHA-n9K9bQn_ZMf2AIuW-THsIayL16_a-zk1m3FWe5733qPQm2Yt7xk7L9q9EbEamHxv19Hdz8t2rybzTrw9Fgm9xvcSTtNxP_gNxy1UNyZ9zelD8ixaB2jhantfX9uarvdLr-tazpwaRP9QXV9KCpsYPhFN_ruJoCfKUfsUZ9RQtcC_VjMht8mhbDsG2YEFpI87KQC7eQgKF0zrQpDZMuFqbMMm3A7SRbMB1HEI0yJ0RZxonhuXXc2US4TFsDyOwJ2aqWlXtGqF4gEbuUJtEu4QuWx7w0gAVYmTjkpwnIu0ujKduyiWNTizPV8CAzhQZW3sABed3pnjccGtdqvfW271Tgv2PVmRTq2-RQHR4n8y-DaKhkQHYvJ0e1DncBGQxEYgi0aRqQV50YXAXvP3TllmvQAXQjISAnN-lAugqohqdRQJ428919EEBhEHCQyI2V0CkgVfempDr94Sm7U-QckjDyvV8zN5hBHRWjvv_1_H-UX5K7w-l4pEafJ8c75B7AOta8mNwlW6t67fYAOq3Mi9ZB_gALaBFh |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFD4amzTxwv0SGGAEQgIpXeLYcSLxUlKysks1oU3rC7Ls1IHBSKeslRC_nmMnTSlMk-Atko-l2D6fz2f7-DPAy7JgcRhzRFrB7TGjDnxlgsiPNQ-FShVP3WbOwSgeHrPdMR-vwdvFXZhGH6LbcLPIcPO1Bfj5pNxeioZ-Lc5Uj1rGfQ02WIxosZTo41I8Kkndw6cORjgPR504Kd1e1l0JRxu2Z39cxjX_Tpn8ncq6WJTfhE-LVjQpKN9685nuFT__EHj832beghstSSX9xqtuw5qp7sDmQXsMfxeyvDaGZKd14R7_qj6To_n3aU0Goz5RF0SRQZPAh9WJvQxkaoLcmLyzCfAzkllHq-_Bcf7-KBv67WsMfoFryMSPuJkIJGgqpUqXmgoTcl0midKIaUEnVIUBhrrEcF6WIdNRWpjIFIybRBUaad99WK-mlXkIRE2syrsQminDoglNw6jUSDRoyYwVv_Hg9WJQZNFKldsXM85kI7JMpe0V6XrFgxed7Xkj0HGp1Ss3tp0Jtt2mtAkuT0Y7cmePjQ_zYCiFB1uLwZctmi9weYRhHqN4HHvwvCtGHNrDFVWZ6RxtkDoJjPbsKhtcCyNliuLAgweNP3U_hDwbCyIsESue1hlYHfDVkur0i9MDj62gkcCab5wjXdENcjfb77uvR_9i_Aw2Dwe53P8w2nsM15Ey0uY25hasz-q5eYK0bKafOvT9AmaOL10 |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Free+Circulating+Tumor+DNA+as+a+Diagnostic+Marker+for+Breast+Cancer&rft.jtitle=Journal+of+clinical+laboratory+analysis&rft.au=Hashad%2C+D.&rft.au=Sorour%2C+A.&rft.au=Ghazal%2C+A.&rft.au=Talaat%2C+I.&rft.date=2012-11-01&rft.pub=John+Wiley+and+Sons+Inc&rft.issn=0887-8013&rft.eissn=1098-2825&rft.volume=26&rft.issue=6&rft.spage=467&rft.epage=472&rft_id=info:doi/10.1002%2Fjcla.21548&rft_id=info%3Apmid%2F23143630&rft.externalDocID=PMC6807470 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0887-8013&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0887-8013&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0887-8013&client=summon |